$3.05
8.54% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US7602731025
Symbol
RPTX
Sector
Industry

Repare Therapeutics Inc Stock price

$3.05
-0.43 12.36% 1M
-0.07 2.24% 6M
-4.25 58.22% YTD
-1.77 36.72% 1Y
-23.08 88.33% 3Y
-27.75 90.10% 5Y
-27.75 90.10% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.24 8.54%
ISIN
US7602731025
Symbol
RPTX
Sector
Industry

Key metrics

Market capitalization $129.66m
Enterprise Value $-47.21m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.61
EV/Sales (TTM) EV/Sales -0.71
P/S ratio (TTM) P/S ratio 1.95
P/B ratio (TTM) P/B ratio 0.74
Revenue growth (TTM) Revenue growth 18.19%
Revenue (TTM) Revenue $66.52m
EBIT (operating result TTM) EBIT $-91.30m
Free Cash Flow (TTM) Free Cash Flow $-77.68m
Cash position $179.43m
EPS (TTM) EPS $-2.00
P/E forward negative
P/S forward 2.30
EV/Sales forward negative
Short interest 2.92%
Show more

Is Repare Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Repare Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Repare Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Repare Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Repare Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
67 67
18% 18%
100%
- Direct Costs 1.97 1.97
52% 52%
3%
65 65
24% 24%
97%
- Selling and Administrative Expenses 30 30
13% 13%
45%
- Research and Development Expense 124 124
1% 1%
186%
-89 -89
10% 10%
-134%
- Depreciation and Amortization 1.97 1.97
52% 52%
3%
EBIT (Operating Income) EBIT -91 -91
12% 12%
-137%
Net Profit -84 -84
14% 14%
-126%

In millions USD.

Don't miss a Thing! We will send you all news about Repare Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Repare Therapeutics Inc Stock News

Neutral
Business Wire
14 days ago
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib.
Neutral
Business Wire
19 days ago
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results.
Neutral
Business Wire
about one month ago
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial.
More Repare Therapeutics Inc News

Company Profile

Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using synthetic lethality approach in Canada. It provides SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company's lead product candidate is RP-3500 a potent and selective oral small molecule inhibitor of ATR for the treatment of tumors with mutations in ataxia-telangiectasia mutated kinase. It also develops CCNE1-SL, a proprietary drug discovery program for tumors with amplification of CCNE1; and polymerase theta inhibitor. The company was founded in 2016 and is headquartered in St. Laurent, Canada.

Head office Canada
CEO Lloyd Segal
Employees 179
Founded 2016
Website www.reparerx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today